Impact of Prior Treatment History on Recurrence After Complete Response to Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

ABSTRACT Aim Integration of locoregional treatments (LRTs) with atezolizumab plus bevacizumab (atezo/bev) has improved treatment outcomes, enabling an increasing number of patients with unresectable hepatocellular carcinoma (HCC) to achieve a complete response (CR). A comprehensive analysis of recur...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tasuku Nakabori, Masaki Kawabata, Kaori Mukai, Hidenari Hongyo, Noboru Maeda, Makiko Urabe, Yugo Kai, Ryoji Takada, Kenji Ikezawa, Hiroshi Wada, Kunihito Gotoh, Kazuyoshi Ohkawa
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2026-02-01
coleção:	Cancer Medicine
Assuntos:	atezolizumab plus bevacizumab hepatocellular carcinoma immunotherapy recurrence
Acesso em linha:	https://doi.org/10.1002/cam4.71552
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!